The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 23, 2012
Filed:
Mar. 21, 2008
Linda C. Burkly, West Newton, MA (US);
Janine L. Ferrant-orgettas, Gloucester, MA (US);
Ellen A. Garber, Cambridge, MA (US);
Yen-ming Hsu, Lexington, MA (US);
Lihe Su, Reading, MA (US);
Frederick R. Taylor, Milton, MA (US);
Ralph Adams, Slough, GB;
Derek Thomas Brown, Slough, GB;
Andrew George Popplewell, Slough, GB;
Martyn Kim Robinson, Slough, GB;
Anthony Shock, Slough, GB;
Kerry Louise Tyson, Slough, GB;
Linda C. Burkly, West Newton, MA (US);
Janine L. Ferrant-Orgettas, Gloucester, MA (US);
Ellen A. Garber, Cambridge, MA (US);
Yen-Ming Hsu, Lexington, MA (US);
Lihe Su, Reading, MA (US);
Frederick R. Taylor, Milton, MA (US);
Ralph Adams, Slough, GB;
Derek Thomas Brown, Slough, GB;
Andrew George Popplewell, Slough, GB;
Martyn Kim Robinson, Slough, GB;
Anthony Shock, Slough, GB;
Kerry Louise Tyson, Slough, GB;
UCB Pharma, S.A., Brussels, BE;
Biogen Idec MA Inc., Cambridge, MA (US);
Abstract
This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.